Human Genome Sciences, Inc. to Report Successful Clinical Study Results of Its PICSO® System Designed to Improve Myocardial Perfusion Following Primary PCI

VIENNA--(BUSINESS WIRE)--Miracor Medical Systems GmbH announced today that data will be reported during next week’s “TCT (Transcatheter Cardiovascular Therapeutics) 2011” scientific meeting in San Francisco. The data show that the PICSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion) system is safe and feasible during elective percutaneous coronary intervention (PCI) using a femoral vein approach. (Click here for 5 minute “Corporate Preview” video with PICSO® animation.)
MORE ON THIS TOPIC